ROS1 (G2101C)
Sign in to save this workspaceROS1 · Variant type: point · HGVS: p.G2101C
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Repotrectinib | 99.7% | 0.3% | 84.21 |
| 2 | Gilteritinib | 99.4% | 0.6% | 88.97 |
| 3 | Lazertinib | 99.1% | 0.9% | 97.47 |
| 4 | Pacritinib | 98.6% | 1.4% | 88.64 |
| 5 | Entrectinib | 98.1% | 1.9% | 93.69 |
| 6 | Tivozanib | 96.0% | 4.0% | 92.42 |
| 7 | Pralsetinib | 94.2% | 5.8% | 93.43 |
| 8 | Darovasertib | 88.2% | 11.8% | 96.99 |
| 9 | Defactinib | 83.7% | 16.3% | 92.68 |
| 10 | Capmatinib | 80.0% | 20.0% | 99.75 |
| 11 | Abemaciclib | 79.8% | 20.2% | 91.48 |
| 12 | Fedratinib | 79.3% | 20.7% | 96.21 |
| 13 | Selpercatinib | 74.1% | 25.9% | 96.72 |
| 14 | Alpelisib | 63.0% | 37.0% | 97.22 |
| 15 | Avapritinib | 43.7% | 56.3% | 97.73 |
| 16 | Sunitinib | 42.1% | 57.9% | 91.73 |
| 17 | Pirtobrutinib | 41.8% | 58.2% | 99.49 |
| 18 | Vandetanib | 39.4% | 60.6% | 95.74 |
| 19 | Tenalisib | 35.8% | 64.2% | 97.98 |
| 20 | Neratinib | 22.3% | 77.7% | 93.18 |
| 21 | Pexidartinib | 18.9% | 81.1% | 99.49 |
| 22 | Erlotinib | 16.4% | 83.6% | 99.75 |
| 23 | Infigratinib | 14.9% | 85.1% | 98.24 |
| 24 | Selumetinib | 14.6% | 85.4% | 100.00 |
| 25 | Futibatinib | 12.1% | 87.9% | 98.48 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Repotrectinib | 99.7% | — | — |
| Gilteritinib | 99.4% | — | — |
| Lazertinib | 99.1% | — | — |
| Pacritinib | 98.6% | — | — |
| Entrectinib | 98.1% | — | — |
| Tivozanib | 96.0% | — | — |
| Pralsetinib | 94.2% | — | — |
| Darovasertib | 88.2% | — | — |
| Defactinib | 83.7% | — | — |
| Capmatinib | 80.0% | — | — |
| Abemaciclib | 79.8% | — | — |
| Fedratinib | 79.3% | — | — |
| Selpercatinib | 74.1% | — | — |
| Alpelisib | 63.0% | — | — |
| Avapritinib | 43.7% | — | — |
| Sunitinib | 42.1% | — | — |
| Pirtobrutinib | 41.8% | — | — |
| Vandetanib | 39.4% | — | — |
| Tenalisib | 35.8% | — | — |
| Neratinib | 22.3% | — | — |
| Pexidartinib | 18.9% | — | — |
| Erlotinib | 16.4% | — | — |
| Infigratinib | 14.9% | — | — |
| Selumetinib | 14.6% | — | — |
| Futibatinib | 12.1% | — | — |
Cancer associations
| Cancer | Organ | Source |
|---|---|---|
| carcinoma_lung | Lung | ref |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 12.9ms